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Previous data showed that prostaglandin E2 (PGE2) mediates the inhibitory effect of bradykinin (BK) on
proximal tubule (PT) Na+-ATPase activity. The aim of this work was to investigate the molecular mech-
anisms involved in the effect of PGE2 on PT Na
+-ATPase. We used isolated basolateral membrane
(BLM) from pig PT, which expresses several components of different signaling pathways. The inhibitory
effect of PGE2 on PT Na+-ATPase activity involves G-protein and the activation of protein kinase A (PKA)
because: (1) PGE2 increased [
35S]GTPcS binding; (2) GDPbS abolished the inhibitory effect of PGE2; (3)
PGE2 increased PKA activity; (4) the inhibitory effect of PGE2 was abolished by PKA inhibitor peptide.
We observed that the PKA-mediated inhibitory effect of PGE2 on PT Na+-ATPase activity requires previous
activation of protein kinase C. In addition, we observed that PGE2 stimulates Ca2+-independent phospho-
lipase A2 activity representing an important positive feedback to maintain the inhibition of the enzyme.
These results open new perspectives to understanding the mechanism involved in the effect of PGE2 on
proximal tubule sodium reabsorption.
 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Prostaglandins (PGs) are lipid messengers that have important
effects on renal function [1]. They are produced by coordinated ac-
tion of phospholipases A2 (PLA2)1 and cyclooxygenases (COX-1 and
COX-2) [1]. The release of these PGs could be induced by peptides
such as bradykinin (BK) that modulates the activity of PLA2 and/or
COX [2–4]. The main renal PG is PGE2 which plays a critical role in
maintaining Na+ balance due to hemodynamic and tubular effects
[1].
The effects of PGE2 on renal sodium excretion have been corre-
lated with changes in distal segments of the nephron [5,6]. This
idea is reinforced by the observation that prostanoid receptors
(EP) are mainly expressed in distal nephron segments [7]. How-
ever, a recent study showed expression of prostanoid receptors
(EP1–EP4) and the effect of PGE2 in primary cultures of rabbit PT
cells, increasing the signiﬁcance of the effect of PGE2 on proximal
tubule (PT) cells [8]. This observation agrees with the proposal thates).
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r chromatography; Tris,
evier OA license.modulation of sodium reabsorption in PT is a crucial mechanism to
determine renal sodium excretion [9]. However, the effect of PGE2
on PT sodium reabsorption and the molecular mechanism involved
are poorly understood.
In previous papers, we observed that BK, through the B2 recep-
tor, inhibits ouabain-insensitive PT Na+-ATPase activity through
activation of the Ca2+-independent PLA2 (iPLA2)/COX pathway
[10]. In addition, we showed that arachidonic acid (AA) and PGE2
mimicked the effect of BK [10]. These data suggest that PGE2 medi-
ates the effect of BK on PT Na+-ATPase. Based on this information,
the aim of this paper was to investigate the molecular mechanism
involved in the inhibition of PT Na+-ATPase by PGE2 and whether
iPLA2 is a target for PGE2, which could represent an important po-
sitive feedback.Materials and methods
Materials
ATP, ouabain, furosemide, EGTA, HEPES, Tris, bradykinin(Arg-
Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), des-Arg9-[Leu8]-BK (DALBK),
1,2-dipalmitoyl-phosphatidylcholine (DPPC) were purchased from
Sigma Chemical Co., St. Louis, MO, USA. Percoll was obtained from
Pharmacia Biotech, Uppsala, Sweden. Palmitoyl triﬂuoromethyl ke-
tone (PACOCF3) was purchased from Calbiochem-Novabiochem
Co., San Diego, CA, USA. All other reagents were of the highest pur-
ity available. [32P]Pi was obtained from the Institute of Energetic
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line, 1-palmitoyl-2-[1-14C]palmitoyl was obtained from Amersham
Pharmacia Biotech UK Limited. Silica gel 60 thin-layer chromatog-
raphy (TLC) plates and all solvents used were obtained from Merck
KGaA, Darmstadt. All solutions were prepared with deionized
glass-distilled water. [c-32P]ATP was prepared as described by
Maia et al. [11].
Isolated basolateral membranes
The basolateral membranes (BLM) of proximal tubules were
isolated and puriﬁed using the Percoll gradient method as de-
scribed previously [12]. The membrane preparation was resus-
pended in 250 mM sucrose at a ﬁnal concentration of 5–10 mg
protein/ml and stored at 20 C. The (Na++K+)ATPase activity, a
marker for BLMs, was 10–12 times higher than the activity found
in the cortex. Residual contamination with other subcellular mem-
brane fractions was minimal. Protein concentration was deter-
mined by the Folin phenol method [13] using bovine serum
albumin as a standard.
Measurement of Na+-ATPase activity
The composition of the assay medium for the measurement of
Na+-ATPase activity (0.1 ml) was: 4 mMMgCl2; 4 mM ATP (speciﬁc
activity about 104 Bq/nmol ATP); 20 mM HEPES–Tris (pH 7.0);
90 mM NaCl; 108 M DALBK; 1 mM ouabain. The ATPase activity
was measured according to the method described by Grubmeyer
and Penefsky [14]. The reaction was started by the addition of
the membranes to the assay medium to a ﬁnal protein concentra-
tion of 0.3–0.5 mg/ml, and stopped after 10 min by the addition of
0.1 N HCl-activated charcoal. The [32P]Pi released was measured in
an aliquot of the supernatant obtained after centrifugation of the
charcoal suspension for 5 min at 2000 rpm in a clinical centrifuge.
Spontaneous hydrolysis of [c-32P]ATP was measured simulta-
neously in tubes to which protein was added after the acid. The
Na+-ATPase activity was calculated from the difference between
the [32P]Pi released in the absence and in the presence of 2 mM
furosemide, both in the presence of 1 mM ouabain [15].
Measurement of PLA2 activity
The PLA2 activity was measured according to the method de-
scribed by Yang et al. [16]. The assay utilized 100 lM DPPC (con-
taining 5.0  105 cpm of L-3-phosphatidylcholine, 1-palmitoyl-2-
[1-14C]palmitoyl) in 0.8 mM Triton X-100, mixed micelles in
200 mM HEPES (pH 7.0), 5 mM EDTA, 2 mM DTT, 1 mM ATP and
108 M DALBK. The reaction was started by the addition of isolated
BLMs to a ﬁnal protein concentration of 0.3 mg/ml. The free fatty
acid released was extracted from isolated BLMs following the
method of Horwitz and Perlman, modiﬁed by Malaquias and Oli-
veira [17]. The lipid samples were applied to TLC silica gel plates
along with phospholipid standards. Prior to lipid loading, the plates
were activated at 110 C for 10 min. TLC was developed in two sol-
vent mixtures: CHCl3/CH3OH/H2O (65:35:5 by vol.) and C6H14/
CH3CH2OCH2CH3/CHOOH (90:60:4 by vol.). The region of the TLC
plate containing free fatty acid was identiﬁed with iodine vapor
and scraped into scintillation vials. The radioactivity was quanti-
ﬁed in a liquid scintillation counter (Packard Tri-carb model
A2100TR, IL, USA).
[35S]GTPcS binding assay
The [35S]GTPcS binding assay was carried out using isolated
BLM as previously described by Lazareno et al. [18]. The composi-
tion of the reaction medium (50 lL) was: 100 mM NaCl, 10 mMMgCl2, and 20 mM HEPES–Tris (pH 7.0). The isolated BLMs
(1 mg/mL) were incubated with 5 nM [35S]GTPcS, varying the con-
centrations of PGE2 from 1012 to 106 M. The assay tubes were
incubated for 1 min at 37 C and the reaction was stopped by the
addition of an ice-cold solution containing 100 mM NaCl, 10 mM
MgCl2 and 20 mM HEPES–Tris (pH 7.0). The samples were immedi-
ately ﬁltered on a borosilicate ﬁlter (MFS Advantec Inc. GB140,
25 mm diameter). The basal binding was assessed in the absence
of the agonist, and non-speciﬁc binding was measured in the pres-
ence of 1 mM unlabeled GTP.
Measurement of protein kinase activity
The activity of protein kinase C (PKC) and protein kinase A (PKA)
was measured by incorporation of 32Pi from [c32-P]ATP (7 lCi/
lmol) to histone sensitive to 108 mol/L calphostin C (Cph C) and
108 M PKA inhibitor peptide (PKAi), respectively. The composition
of the reaction medium was: 4 mM MgCl2, 20 mM HEPES–Tris (pH
7.0), 1.5 mg/ml histone and 0.7 mg/ml protein. The reaction was
stopped with 40% trichloroacetic acid (TCA) and the sample imme-
diately placed on ice. An aliquot (0.1 ml) was ﬁltered through a
Millipore ﬁlter (0.45 lm) and washed with ice-cold 20% TCA solu-
tion and 0.1 M phosphate buffer (pH 7.0). The radioactivity was
quantiﬁed by liquid scintillation counting (Packard Tri-Carb 2100
TR). The speciﬁc PKC and PKA activities were calculated from the
difference between the activity in the absence and in the presence
of 108 M calphostin C and 108 M PKAi, respectively. The phorbol
ester (PMA) was used as PKC activator and cAMP was used as PKA
activator.
Data analysis
The means were compared by one-way analysis of variance
(ANOVA) taking into account the treatment of the experimental
groups. The magnitudes of the differences were evaluated using
the multiple comparative Bonferroni test. The data are presented
as the mean ± standard error (mean ± SE). The n corresponds to
the results obtained from different BLM preparations.Results
Heterotrimeric G-protein is involved in the inhibitory effect of PGE2 on
Na+-ATPase activity
In the present work we used BLM isolated from pig PT. In a pre-
vious paper we showed that in this preparation, PGE2 and BK inhi-
bit Na+-ATPase without change in (Na++K+)ATPase activity [19].
Furthermore, the expression and functionality of several compo-
nents of different signaling pathways, including guanine nucleo-
tide binding proteins (G proteins), phospholipases and protein
kinases in isolated BLM, have been shown [20–22]. Therefore,
BLM is a good model to study the molecular mechanisms involved
in the modulation of PT Na+-ATPase.
It is well known that EP receptor-induced effects are mediated
by the family of heterotrimeric G proteins [7]. In the ﬁrst experi-
mental group, we tested the involvement of heterotrimeric G-pro-
teins in the inhibitory effect of PGE2 on BLM Na+-ATPase activity.
Initially we measured the incorporation of [35S]GTPcS in BLM in-
duced by PGE2. It can be observed that PGE2 increased [35S]GTPcS
binding in a dose-dependent manner with maximum effect ob-
served at 108 M (Fig. 1A). PGE2 at concentrations as low as
1012 M was already able to induce a signiﬁcant increase in
[35S]GTPcS binding.
The correlation between PGE2-induced heterotrimeric G protein
activity and the inhibition of Na+-ATPase activity was assessed
Fig. 1. Involvement of a heterotrimeric G protein in the inhibitory effect induced by
PGE2 and BK on BLM Na+-ATPase activity. (A) PGE2-induced dose-dependent
increase in [35S]GTPcS binding to isolated BLM. Non-speciﬁc binding is deﬁned as
the binding in the presence of 1 mM GTP, which was less than 10% of the total
binding. ⁄Statistically signiﬁcant compared with control (p < 0.05, n = 4). (B)
Modulation of the inhibitory effect of PGE2 on BLM Na+-ATPase activity by
106 M GDPbS, heterotrimeric G-protein inhibitor. Na+-ATPase activity was mea-
sured as described in Materials and methods section. Statistically signiﬁcant
compared with ⁄control and #in the presence BK or PGE2 plus GDPbS (p < 0.05,
n = 6). All data are expressed as means ± SE.
Fig. 2. Involvement of PKA on PGE2 and BK-mediated inhibition of Na+-ATPase
activity. (A) Effect of 106 M PGE2 or 109 M BK on PKA activity. cAMP was used as
the activator of PKA. PKA activity was measured by PKA inhibitor peptide (iPKA)-
sensitive histone phosphorylation as described in Materials and methods section.
⁄Statistically signiﬁcant compared with control (p < 0.05, n = 8). (B) Modulation of
the effect of PGE2 or BK on Na+-ATPase activity by 108 M iPKA. Na+-ATPase activity
was measured as described in Materials and methods section. Statistically
signiﬁcant compared with ⁄control and #in the presence of iPKA (p < 0.05, n = 6).
(C) Modulation of the effect induced by PGE2 or BK on Na+-ATPase by 109 M
cholera toxin (CTX), an activator of Gs protein, or 109 M FSK, an activator of
adenylyl cyclase. ⁄Statistically signiﬁcant compared with control (p < 0.05, n = 8). All
data are expressed as means ± SE.
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vious paper, we observed that PGE2 inhibits PT Na+-ATPase activity
in a dose-dependent manner with maximal effect at 1010 M and
maintained up to 106 M. Similarly in the present work we ob-
served that the addition of 106 M PGE2 decreased Na+-ATPase
activity by 41%. Furthermore, this effect was completely reversed
by 106 M GDPbS (Fig. 1B). The addition of 106 M GDPbS did not
change the enzyme activity. These results show that PGE2 activates
heterotrimeric G protein, which mediates the inhibition of PT Na+-
ATPase activity. We then decided to investigate the signaling path-
way involved in the PGE2 effect.
Role of PKA and PKC in the inhibition of Na+-ATPase activity by PGE2
and BK
Fig. 2A shows the effect of 106 M PGE2 and 109 M BK on PKA
activity. 106 M PGE2 increased PKA activity by 200% in a similar
way to 109 M BK and 108 M cAMP. The correlation between acti-
vation of PKA and inhibition of Na+-ATPase activity induced by
106 M PGE2 or 109 M BK was assessed using the inhibitor peptide
of PKA (iPKA, Fig. 2B). The simultaneous addition of 108 M iPKA
and 106 M PGE2 or 109 M BK completely prevented the inhibi-
tory effect of both compounds. The addition of 108 M iPKA did
not change the enzyme activity.Usually the activation of PKA is preceded by activation of aden-
ylyl cyclase by Gs protein [23]. Fig. 2C shows that addition of
109 M cholera toxin (CTX), an activator of Gs protein, or 106 M
forskolin (FSK), an activator of adenylyl cyclase, did not change
the inhibitory effect of 109 M BK or 106 M PGE2 on PT Na+-ATP-
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ATPase activity by 57% and 52%, respectively. In addition, we
showed in a previous work that the activation of PKA promotes
an increase in Na+-ATPase activity [24]. These results indicate that
an event occurs simultaneously to PGE2-induced PKA activation
that promotes modulation of the PKA effect on PT Na+-ATPase
activity. An important clue comes from the observation that when
PKC is activated, further enhancement in PKA activity decreases PT
Na+-ATPase activity [25]. In addition, it has also been shown that
BK induces PKC activation prior to activation of iPLA2 [10].
Based on these observations we decided to investigate whether
PKC could be activated by PGE2. It can be observed that 106 M
PGE2 enhances PKC activity by 137% in a similar way to 1012 M
phorbol ester PMA, an activator of PKC (Fig. 3A). In addition, it
was observed that 109 M calphostin C, an inhibitor of PKC, com-
pletely abolished the inhibitory effect of PGE2 on PT Na+-ATPase
activity (Fig. 3B). These data show the correlation between PGE2-
induced PKC activation and inhibition of PT Na+-ATPase activity.
So far our results indicate that the PKA-mediated inhibitory ef-
fect of PGE2 requires previous activation of PKC. To conﬁrm this
hypothesis we pre-incubated isolated BLM with 1012 M PMA for
30 min. The enzyme activity was then measured in the absence
or in the presence of 106 M FSK, 109 M BK or 106 M PGE2
(Fig. 3C). It was observed that the enzyme activity was increased
by 142% by pre-incubation with PMA. Further addition of 106 M
FSK decreased PT Na+-ATPase activity to a lower level than that ob-
served in the absence of PMA (control). This effect of FSK is the
opposite to that observed in the absence of prior PKC activation
as shown in Fig. 2C. Furthermore, 109 M BK or 106 M PGE2 also
decreased the enzyme activity in a similar way to FSK.
These results show that PGE2 induces activation of PKC activity
with prior activation of PKA in a similar way to that observed pre-
viously for BK. However, one question remains: is PGE2 able to acti-
vate PLA2 activity in a similar way to BK?Fig. 3. PKA-mediated inhibitory effect of PGE2 requires the previous activation of
PKC. (A) Effect of 106 M PGE2 on PKC activity. When indicated 1012 M phorbol
ester (PMA), a PKC activator, was added. The PKC activity was measured by
calphostin C (Cph)-sensitive histone phosphorylation as described in Materials and
methods section. ⁄Statistically signiﬁcant compared with control (p < 0.05, n = 5).
(B) The inhibitory effect induced by PGE2 on Na+-ATPase activity was blocked by
108 M Cph C, a PKC inhibitor. Na+-ATPase activity was measured as described in
Materials and methods section. Statistically signiﬁcant compared with ⁄control and
#in the presence of PGE2 and Cph C (p < 0.05, n = 7). (C) BLMwas pre-incubated with
1012 M PMA for 30 min. Na+-ATPase activity was measures in the absence or in the
presence of 106 M FSK, 109 M BK or 106 M PGE2 as indicated in the ﬁgure.
Statistically signiﬁcant compared with ⁄control and #in the presence of PMA
(p < 0.05, n = 6). All data are expressed as means ± SE.Stimulation of PLA2 activity by PGE2
In a previous paper we showed that BK increased Ca2+-indepen-
dent PLA2 (iPLA2) [10]. The formation of AA by PLA2 indicates that
PGE2 is formed through the action of COX [1]. On the other hand, it
has been shown that PGE2 increases COX-1, COX-2 and PLA2 pro-
tein expression in mouse lung ﬁbroblast cells [26], which could
represent a very important positive loop in modulation of the pro-
stanoid cascade. In this study, we investigated the possibility that
PGE2 modulates iPLA2 activity in PT. To investigate this issue, the
BLM were incubated with 106 M PGE2 and the PLA2 activity was
measured by the AA formed. Fig. 4A shows the time course of
the effect of 106 M PGE2 on PLA2 activity. It was observed that
PGE2 stimulates PLA2 activity by 100%. The maximal stimulation
was observed after pre-incubation for 10 min, returning to the con-
trol level after incubation for 20 min with PGE2.
To determine if PGE2 modulates the same PLA2 isoform type as
BK, we performed experiments in the presence of PACOCF3 or
bromoenol lactone (BEL), speciﬁc inhibitors of iPLA2 (Fig. 4B). All
experiments were performed in the presence of 1 mM EGTA and
in the absence of added Ca+2. Under these conditions, 106 M PA-
COCF3 or 106 M BEL completely abolished the stimulatory effect
of PGE2 on PLA2 activity, conﬁrming that PGE2 modulates the same
PLA2 isoform type as BK.Discussion
In the present work we have shown that PGE2 inhibits PT Na+-
ATPase activity via a heterotrimeric G-protein coupled to the
cAMP/PKA/iPLA2 pathway, which requires previous activation ofPKC. These results open new perspectives to understanding the
mechanism involved in the effect of PGE2 on renal sodium excre-
tion during physiological and pathological conditions.
The evidence from the present work and a previous study indi-
cates that PGE2 mediates the effect of BK on PT Na+-ATPase: (1) AA
and PGE2 have a similar and non-additive effect on BK; (2) the ef-
fect of BK is completely abolished by COX and iPLA2 inhibitors.
However, how BK induces release of PGE2 in PT is not completely
Fig. 4. PGE2 modulates iPLA2 activity in PT BLM. (A) Time course of the effect of
PGE2 on PLA2 activity. PGE2-induced change in PLA2 activity was calculated from
the difference between fatty acid formed in the presence and in the absence of
106 M PGE2 and expressed as a percentage of the increase, for the times shown.
The PLA2 activity was measured as described in Materials and methods section.
⁄Statistically signiﬁcant compared with control (p < 0.05, n = 4). (B) Modulation of
the stimulatory effect of 106 M PGE2 on PLA2 activity by 106 M PACOCF3 and
106 M BEL. The enzyme activity was measured as described in Materials and
methods section. ⁄Statistically signiﬁcant compared with control (p < 0.05, n = 5).
All data are expressed as means ± SE.
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role of these iPLA2 in kidney function is poorly understood. Usually,
iPLA2 plays a crucial role in remodeling of phospholipids, which
could be associated with induction of apoptosis [27]. The possible
involvement of iPLA2 in the production of PGE2 has been shown in
only a few cell types [2,28,29]. Akiba et al. [28] showed that, in
macrophage-like P388D1 cells, inhibition of iPLA2 with antisense
oligonucleotide for iPLA2 decreases PGE2 production. The same
group also showed that, in mesangial cells, BEL abolishes IL-1b
and dibutyryl cAMP-stimulated PGE2 production [29]. Murakami
et al. [2] showed that iPLA2 induces generation of PGE2 coupled
to COX-1 in human embryonic kidney 293 cells. Similarly, we ob-
served that BEL completely abolished the inhibitory effect of BK
on PT Na+-ATPase activity [10] and PGE2 mimicked it.
The autocrine and paracrine effects of PGE2 are mediated by
speciﬁc G-protein coupled receptors, EP1–EP4 receptors [7]. For a
long time, the presence of EP receptors in proximal tubule was
not evident. A very recent paper showed that EP1–EP4 receptors
were expressed in a primary culture of rabbit proximal tubule cells
[8]. Here, we have shown that the effect of PGE2 on PT Na+-ATPase
activity involves activation of CTX-sensitive G protein.
Reports usually suggest that activation of EP2 and EP4 receptors
increases the level of cAMP and consequently PKA activity [7]. The
observation that the inhibitory effect of PGE2 on PT Na+-ATPase
activity involves activation of PKA could suggest the involvement
of these receptors in the effect of PGE2. Supporting this idea is
the observation that EP1 receptor is coupled to the IP3/Ca2+ path-
way [7], and EP3 receptor activation leads to a decrease in the levelof cAMP [7]. Because we also observed that the effect of PGE2 de-
pends on the activation of PKC, it is not possible to determine
the speciﬁc receptor type that mediates the effect of PGE2 on PT
Na+-ATPase activity.
The molecular mechanism of modulation of PT Na+-ATPase
activity involves an interdependent network. The results obtained
in the present paper together with earlier results show that PGE2-
mediated BK inhibition of PT Na+-ATPase activity depends on
sequential activation of the PI-PLCb/PKC and cAMP/PKA pathways.
It has been shown that the activation of both pathways separately
promotes activation of the enzyme [24,30]. However, when PKA
activation is preceded by a previous activation of PKC inhibition
of PT Na+-ATPase activity occurs [25]. One possible explanation
for these results is that the activation of PKC promotes exposure
of a PKA phosphorylation site leading to inhibition of the enzyme.
However, further experiments are necessary to clarify this issue.
PGE2 was able to increase iPLA2 activity, which could represent
an important positive feedback to maintain inhibition of the en-
zyme. The mechanism of activation of iPLA2 by PGE2 was not di-
rectly investigated but it is well known that iPLA2 could be
activated by PKC [27]. Furthermore, we showed that PGE2 in-
creases PKC activity. Therefore, it is plausible to postulate that
PGE2 increases iPLA2 activity through activation of PKC.
It is well known that PGE2 has important effects on renal so-
dium excretion [1]. Usually, the tubular effects of PGE2 on renal so-
dium excretion are associated with modiﬁcations in distal
segments of the nephron, but a functional role for PGE2 in the PT
has been less studied [5,6]. A role of PT reabsorption in renal so-
dium excretion has been suggested mainly by the observation that
in chronic diseases such as primary hypertension there are speciﬁc
changes in PT sodium reabsorption [9,31]. The possible effect of
PGE2 on sodium reabsorption in PT cells has been shown in LLC-
PK1 cells and in primary cultures of rabbit PT cells [8,32]. Here
we observed that PGE2 inhibits PT Na+-ATPase activity, which
agrees with the natriuretic effect described for PGE2 [1]. This idea
is supported by the observation that other compounds that have
a natriuretic effect, such as urodilatin and atrial natriuretic peptide,
inhibit Na+-ATPase activity [33].
In a previous paper we observed that both BK and PGE2 did not
change the (Na++K+)ATPase activity in BLM of PT [19]. These results
are contrary to what was observed by Herman et al. [8]. These
authors showed that chronic incubation of primary rabbit renal
PT cells rat with PGE1 and PGE2 increased (Na++K+)ATPase expres-
sion. The differences observed could be explained by the time of
incubation and/or the preparation used. In the present work, we
used BLM isolated from PT and only the acute effect of PGE2 was
evaluated. In agreement with this proposal, Gallicchio and Bach
[32] observed that PGE2 decreased (Na++K+)ATPase expression in
LLC-PK1 cells incubated for 30 min. In addition, BLM isolated from
PT contains components of different signaling pathways including
G proteins, phospholipases and protein kinases [20–22].
The inhibition of COX has been associated with the develop-
ment of hypertension [34]. In addition, Jia et al. [35] proposed
that PGE2 reduces hypertension, sodium retention and kidney in-
jury in a deoxycorticosterone acetate-salt hypertension mice
model. These results indicate that PT Na+-ATPase could be a pos-
sible target for PGE2 during the modulation of renal sodium
excretion under physiological and pathological conditions such
as hypertension. This hypothesis is supported by the following
observations: (1) the activity of this enzyme is enhanced in adult
spontaneously hypertensive rats (SHR) although (Na++K+)ATPase
is not changed [31]; this result agrees with the observation that
patients with essential hypertension as well as SHR show in-
creased PT sodium reabsorption [36,37]. (2) It has been shown
that abnormal regulation of PT ouabain-insensitive Na+-ATPase
activity is involved in hypertension associated with the metabolic
286 J.D. Líbano-Soares et al. / Archives of Biochemistry and Biophysics 507 (2011) 281–286syndrome [38]. (3) Marín et al. [39] observed that this enzyme
activity is increased in animals fed a high sodium diet for
4 months; this increases the extracellular volume, without chang-
ing the (Na++K+)ATPase activity.
Our results show that the modulation of Na+-ATPase involves
membrane components and may represent an important mecha-
nism for rapid regulation of sodium reabsorption in the proximal
tubule. The results demonstrate the interconnection between the
pathways triggered by BK and PGE2 in the PT sodium transporters,
which could be correlated with renal sodium excretion.Acknowledgments
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